Compare · LONA vs VRTX
LONA vs VRTX
Side-by-side comparison of LeonaBio Inc. (LONA) and Vertex Pharmaceuticals Incorporated (VRTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. LONA focuses on Biotechnology: Biological Products (No Diagnostic Substances), while VRTX focuses on Biotechnology: Pharmaceutical Preparations.
- VRTX is the larger of the two at $135.44B, about 3752.8x LONA ($36.1M).
- VRTX has been more active in the news (10 items in the past 4 weeks vs 7 for LONA).
- VRTX has more recent analyst coverage (25 ratings vs 4 for LONA).
- Company
- LeonaBio Inc.
- Vertex Pharmaceuticals Incorporated
- Price
- -
- -
- Market cap
- $36.1M
- $135.44B
- 1M return
- -
- +6.42%
- 1Y return
- -
- +22.61%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 1991
- News (4w)
- 7
- 10
- Recent ratings
- 4
- 25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Latest LONA
- LeonaBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update
- SEC Form SCHEDULE 13G filed by LeonaBio Inc.
- SEC Form SCHEDULE 13G filed by LeonaBio Inc.
- Large owner Portman David J. bought $9,919,161,281 worth of shares (3,149,470 units at $3,149.47) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by LeonaBio Inc.
- SEC Form 4 filed by LeonaBio Inc.
- LeonaBio Inc. filed SEC Form 8-K: Other Events
- SEC Form 3 filed by new insider Portman David J.
- LeonaBio to Participate in Cantor Global Healthcare Conference 2026
Latest VRTX
- EVP, CO & FO Wagner Charles F Jr sold $8,374,741 worth of shares (15,286 units at $547.87) as part of a pre-agreed trading plan, decreasing direct ownership by 32% to 31,764 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Vertex Pharmaceuticals Incorporated
- A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End
- CEO & President Kewalramani Reshma sold $6,307,135 worth of shares (11,866 units at $531.53) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 86,471 units (SEC Form 4)
- Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
- Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story
- Vertex to Participate in Upcoming Investor Conferences
- SEC Form 10-Q filed by Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Vertex Reports Third Quarter 2026 Financial Results